KIF18A and cancer: Given that Cdk1 is a key kinase that activates the SAC and that inhibiting Wee1 extends mitosis in a SAC-dependent manner, it can be hypothesized that combining Wee1 and Kif18A inhibition may potentiate therapeutic effectiveness against aneuploid cancers (Visconti et al., 2015; Toledo et al., 2015).